Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2019
August 02, 2019 at 02:15 pm EDT
Share
Rasna Therapeutics, Inc. announced earnings results for the third quarter ended June 30, 2019. For the third quarter, the company announced operating loss was USD 191,845 compared to USD 809,385 a year ago. Net loss was USD 209,543 compared to USD 803,965 a year ago. Basic eps was USD 0 compared to basic loss per share of USD 0.01 a year ago. For the nine months, operating loss was USD 854,463 compared to USD 3.665 million a year ago. Net loss was USD 876,207 compared to USD 3.670 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.05 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
